Greenwich LifeSciences, Inc.
GLSINasdaq
$16.32
↓ -14.2%Jul 17 close · end-of-day
Price
1Y↑ +45.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$237.7M
Enterprise Value
$237.7M
P/E
—
P/S
—
P/B
45.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$22.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-422.6%
ROIC
-335.8%
Debt / Equity
—
Net Cash
—
Return 1Y
+32.7%
Company profile
Greenwich LifeSciences focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
- CEO
- Snehal S. Patel
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 3
- Headquarters
- Texas
- Website
- greenwichlifesciences.com
Earnings
GLSI Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.39↑ +85.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$1.9M | -$4.6M | -$8.0M | -$9.3M | -$17.6M | -$19.4M |
| Net income | -$1.9M | -$4.6M | -$7.8M | -$8.9M | -$17.4M | -$19.4M |
| Diluted EPS | — | — | -$0.61 | -$0.69 | -$1.34 | -$1.43 |
| Operating cash flow | -$1.2M | -$4.3M | -$6.2M | -$6.5M | -$7.3M | -$9.9M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.7M | -$2.7M | -$9.7M | -$2.8M | -$4.0M | -$4.2M | -$8.5M | -$5.7M |
| Net income | -$2.6M | -$2.7M | -$9.7M | -$2.7M | -$3.7M | -$3.7M | -$9.2M | -$5.7M |
| Diluted EPS | -$0.20 | -$0.20 | -$0.75 | -$0.21 | -$0.28 | -$0.27 | -$0.67 | -$0.39 |
| Operating cash flow | -$1.0M | -$2.6M | -$1.9M | -$1.8M | -$2.2M | -$2.7M | -$3.2M | -$4.7M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 1, 2026
- 49d agoGreenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026finance.yahoo.com
- 49d agoGLSI Stock Climbs After Removing A Key Overhang – Retail Turns Focus To High-Stakes Breast Cancer Trialstocktwits.com
- 49d agoGreenwich LifeSciences Provides Update Regarding Form 10-K Filingfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-01-13 | Patel Snehal· CEO and CFO | Buy | 1,800 | $29.83 | $53,694.00 | filing |
| 2026-01-12 | Patel Snehal· CEO and CFO | Buy | 2,900 | $27.54 | $79,866.00 | filing |
| 2025-12-31 | Patel Snehal· CEO and CFO | Buy | 4,300 | $21.36 | $91,848.00 | filing |
| 2025-12-30 | Patel Snehal· CEO and CFO | Buy | 2,900 | $21.73 | $63,017.00 | filing |
| 2025-12-18 | Patel Snehal· CEO and CFO | Buy | 4,100 | $12.62 | $51,742.00 | filing |
| 2025-11-25 | Patel Snehal· CEO and CFO | Buy | 4,600 | $8.37 | $38,502.00 | filing |
| 2025-11-07 | Patel Snehal· CEO and CFO | Buy | 10,600 | $8.43 | $89,358.00 | filing |
| 2025-10-31 | Patel Snehal· CEO and CFO | Buy | 2,300 | $9.26 | $21,298.00 | filing |
Latest 8 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.